Recent Updates
Recently added Catalysts
BLCO Positive Sentiment

Bausch + Lomb Introduces Orphia™, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care

Thursday, July 9, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Bausch + Lomb has launched Orphia™, an AI-driven digital health platform aimed at streamlining tools for eye care providers. This initiative allows physicians to focus more on patient care rather than managing various disconnected technologies. The platform is designed to be inclusive for all eye care professionals, enhancing overall service delivery.
Price reaction · baseline $16.66 (2026-07-08 close) · hit pre-market · 1 other BLCO headline(s) in the window, move may be shared
day 0 close
+0.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Introduction of an innovative AI-powered platform.
  • Focus on enhancing patient care by reducing administrative burdens.
  • Brand agnostic design to serve all eye care providers.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
1.4%
average across 3 past catalysts
Lead asset
Latanoprostene bunod
Phase 1 · Intraocular Pressure

Full Press Release Details

VAUGHAN, Ontario, & MENLO PARK, Calif.--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the creation of Orphia™, a new AI-powered digital health platform built on the belief that eye care providers should spend less time managing disconnected tools and technologies and more time caring for patients. The platform is brand agnostic and designed to serve all eye care providers, r

Frequently Asked Questions

What is Orphia™?

Orphia™ is an AI-powered digital health platform by Bausch + Lomb.

How does Orphia™ benefit eye care providers?

It reduces the time spent on managing tools, allowing more focus on patient care.

Is Orphia™ designed for specific brands?

No, it is brand agnostic and serves all eye care providers.

Where was Orphia™ announced?

The platform was announced in Vaughan, Ontario, and Menlo Park, California.

ShareAdd on Google
Tags: BLCO Viatris Investor Conferences Healthcare Bausch + Lomb Orphia AI platform eye care digital health
Last updated: Jul 9, 2026

Biotech snapshot

Cash runway
$378M liquidity · $0M/mo burn
Low dilution risk
Lead asset
Latanoprostene bunodPhase 1
Intraocular Pressure →

Catalyst track record

+13%
best trade around BLCO's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for BLCO.

See every catalyst's timing & PoA →